 BURLINGTON, Mass., April 13, 2021 GLOBE NEWSWIRE -- Flexion Therapeutics, Inc. Nasdaq:FLXN today announced preliminary ZILRETTA triamcinolone acetonide extended-release injectable suspension net sales of approximately 24.6 million for the quarter ended March 31, 2021. 